Abstract: A one-hand engageable vacuum tool connection assembly for connection to a commercial vehicle vacuum system that includes: a vacuum tool connection assembly hose having a first end and a second end; an upper assembly and a lower assembly having a tool connector where the tool connector engages a second end of the lower assembly swivel cuff and is typically adapted to receive one or a plurality of different types of vacuum tools. The vacuum tool engagement assembly is typically free of any flapper valve, metal or spring biased elements.

Abstract: The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

Abstract: The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

Abstract: The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Abstract: An additive composition comprises a wax and a nucleating agent. The nucleating agent can be dispersed in the wax. A process for producing a nucleated polymer comprises the steps of (a) providing a reactor; (b) providing an additive composition comprising a wax and a nucleating agent; (c) providing an extruder; (d) reacting in the reactor a reactant mixture comprising an olefin monomer and hydrogen to produce a polyolefin polymer; (e) collecting and recovering the polyolefin polymer produced by the reaction; (f) conveying the polyolefin polymer to the extruder; (g) conveying the additive composition to the extruder; and (g) extruding the polyolefin polymer and the additive composition to produce a nucleated polymer composition.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: An additive composition comprises a wax and a nucleating agent. The nucleating agent can be dispersed in the wax. A process for producing a nucleated polymer comprises the steps of (a) providing a reactor; (b) providing an additive composition comprising a wax and a nucleating agent; (c) providing an extruder; (d) reacting in the reactor a reactant mixture comprising an olefin monomer and hydrogen to produce a polyolefin polymer; (e) collecting and recovering the polyolefin polymer produced by the reaction; (f) conveying the polyolefin polymer to the extruder; (g) conveying the additive composition to the extruder; and (g) extruding the polyolefin polymer and the additive composition to produce a nucleated polymer composition.

Abstract: A polymer composition comprises a thermoplastic polymer, a polymer additive selected from the group consisting of nucleating agents, clarifying agents, and combinations thereof, and a fluoropolymer. A molded article comprises at least one wall defining a cavity, the wall having an opening therein permitting access to the cavity. The wall comprises a polymer composition comprising a thermoplastic polymer, a polymer additive selected from the group consisting of nucleating agents, clarifying agents, and combinations thereof, and a fluoropolymer. A method for molding a polymer composition is also provided.

Abstract: A polymer composition comprises a thermoplastic polymer, a polymer additive selected from the group consisting of nucleating agents, clarifying agents, and combinations thereof, and a fluoropolymer. A molded article comprises at least one wall defining a cavity, the wall having an opening therein permitting access to the cavity. The wall comprises a polymer composition comprising a thermoplastic polymer, a polymer additive selected from the group consisting of nucleating agents, clarifying agents, and combinations thereof, and a fluoropolymer. A method for molding a polymer composition is also provided.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: An additive composition comprises a wax and a nucleating agent. The nucleating agent can be dispersed in the wax. A process for producing a nucleated polymer comprises the steps of (a) providing a reactor; (b) providing an additive composition comprising a wax and a nucleating agent; (c) providing an extruder; (d) reacting in the reactor a reactant mixture comprising an olefin monomer and hydrogen to produce a polyolefin polymer; (e) collecting and recovering the polyolefin polymer produced by the reaction; (f) conveying the polyolefin polymer to the extruder; (g) conveying the additive composition to the extruder; and (g) extruding the polyolefin polymer and the additive composition to produce a nucleated polymer composition.

Abstract: Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.

Abstract: A safety harness tool has a single web member that is used to form two arm loop structures and two leg loop structures for respectively securing the limbs of a body. The loops are primarily formed by stitched certain portions of the single web member to itself. The arm loops are made to have extra material, beyond what is needed to be securely placed around the arms of the body. When the harness tool is in use, the excess portions of the two arm loops are tied to each other and/or adjusted in size using an adjustment ring, such as a double buckle.

Abstract: Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.

Abstract: Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.

Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Abstract: Rope equipment with a pivoting rope clamp including first and second members mechanically connected to each other so that they are free to rotate relative to each other and so that a rope can be secured to (for example, threaded through) the rope equipment. At some relative rotational position, or range of relative rotational positions, the first and second members will be sufficient spaced apart so that the equipment can slide relatively freely with respect to the rope. However, if the relative rotation position changes too much in either rotational direction (clockwise or counterclockwise), then the first and second members will clamp down on the rope and prevent it from sliding with respect to the rope equipment. Preferably, the first member is provided with friction braking holes to help constrain the rope to the rope equipment and also to provide some degree of friction braking on sliding motion between the rope and the rope equipment.